Original Article
Efficacy and Safety of Inhaled Ambroxol Hydrochloride Solution in Chinese Pediatric Patients with Acute Lower Respiratory Tract Infections: A Real-World, Multicenter, Open-Label, Single-Arm Study
Hao Wang, Yingxue Zou, Yunxiao Shang, Mingwu Chen, Zhou Fu, Rong Jin, Yu Tang, Shujun Li, Xiufang Wang, Changshan Liu, Liyuan Tian, Dehui Chen, Kaiyuan Luo, Guanghuan Pi, Yanping Chen, Hongmei Qiao, Lili Zhong, Gen Lu, Xingdong Wu, Yongjun Wang, Xuefang Zheng, Jiangchuan Zhu, Zhiying Han, Ningling Wang, Yuling Han, Zhenkun Zhang, Aiqiong Wang, Yang Liu, Zengqing Li, Ping Xue, Yongfeng Zhang, Wei Xiong, Zhe Xu, Rongxiu Zheng, Rong Jiao, Xiaohui Liu, Churangui Sa, Yuejie Zheng, Qiang Chen, Youjia Xu, Qi Zhang, Qi Gao, Qi Chen, Yungang Yang, Zhuanggui Chen, Lihua Zhu, Juan Lin, Zhimin Chen, Tao Ai, Luyi Ma, Fuling Wu, Leping Ye, Zhengrong Chen, Hanmin Liu, Yi Jiang, Jichun Wang, Yong Yin, Hong Cui, Hailin Zhang, Weihua Gan, Lijun Wang, Xiaoyun Jiang, Xiaoxia Lu, Min Qin, Baoping Xu
Abstract
Although randomized controlled trials have confirmed the mucolytic efficacy of ambroxol hydrochloride solution for inhalation (AHSI) in selected cohorts, their stringent exclusion criteria often omit children with comorbidities and complex presentations encountered in routine practice. Consequently, real-world evidence is needed to evaluate the effectiveness and safety of AHSI in a broader, clinically representative pediatric population with acute lower respiratory tract infections (ALRTIs).
